JP7596257B2 - 一酸化窒素放出性ホスホジエステラーゼ５型阻害薬 - Google Patents

一酸化窒素放出性ホスホジエステラーゼ５型阻害薬 Download PDF

Info

Publication number
JP7596257B2
JP7596257B2 JP2021506326A JP2021506326A JP7596257B2 JP 7596257 B2 JP7596257 B2 JP 7596257B2 JP 2021506326 A JP2021506326 A JP 2021506326A JP 2021506326 A JP2021506326 A JP 2021506326A JP 7596257 B2 JP7596257 B2 JP 7596257B2
Authority
JP
Japan
Prior art keywords
compound
pyrimidin
nitrooxy
ethyl
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021506326A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021533152A5 (enExample
JP2021533152A (ja
Inventor
アルミランテ，ニコレッタ
ブランビッラ，ステファーニア
ストローニ，ラウラ
インパグナッティエッロ，フランチェスコ
バスティア，エレナ
Original Assignee
ニコックス エス．エー．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ニコックス エス．エー． filed Critical ニコックス エス．エー．
Publication of JP2021533152A publication Critical patent/JP2021533152A/ja
Publication of JP2021533152A5 publication Critical patent/JP2021533152A5/ja
Priority to JP2024125823A priority Critical patent/JP2024150732A/ja
Application granted granted Critical
Publication of JP7596257B2 publication Critical patent/JP7596257B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2021506326A 2018-08-06 2019-07-31 一酸化窒素放出性ホスホジエステラーゼ５型阻害薬 Active JP7596257B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024125823A JP2024150732A (ja) 2018-08-06 2024-08-01 一酸化窒素放出性ホスホジエステラーゼ５型阻害薬

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP18187482.7 2018-08-06
EP18187482 2018-08-06
EP18210147.7 2018-12-04
EP18210147 2018-12-04
PCT/EP2019/070597 WO2020030489A1 (en) 2018-08-06 2019-07-31 Nitric oxide releasing phosphodiesterase type 5 inhibitor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024125823A Division JP2024150732A (ja) 2018-08-06 2024-08-01 一酸化窒素放出性ホスホジエステラーゼ５型阻害薬

Publications (3)

Publication Number Publication Date
JP2021533152A JP2021533152A (ja) 2021-12-02
JP2021533152A5 JP2021533152A5 (enExample) 2022-08-08
JP7596257B2 true JP7596257B2 (ja) 2024-12-09

Family

ID=67539493

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021506326A Active JP7596257B2 (ja) 2018-08-06 2019-07-31 一酸化窒素放出性ホスホジエステラーゼ５型阻害薬
JP2024125823A Pending JP2024150732A (ja) 2018-08-06 2024-08-01 一酸化窒素放出性ホスホジエステラーゼ５型阻害薬

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024125823A Pending JP2024150732A (ja) 2018-08-06 2024-08-01 一酸化窒素放出性ホスホジエステラーゼ５型阻害薬

Country Status (11)

Country Link
US (2) US11980618B2 (enExample)
EP (1) EP3833395A1 (enExample)
JP (2) JP7596257B2 (enExample)
KR (1) KR102836746B1 (enExample)
CN (2) CN112566670B (enExample)
AU (1) AU2019319004B2 (enExample)
BR (1) BR112021001950A2 (enExample)
CA (1) CA3108551A1 (enExample)
MX (2) MX2021001503A (enExample)
TW (1) TWI839375B (enExample)
WO (1) WO2020030489A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023516891A (ja) * 2020-02-05 2023-04-21 ニコックス エス．エー． 緑内障及び高眼圧症の処置のための組成物

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111217834B (zh) * 2020-02-21 2021-10-26 维眸生物科技（上海）有限公司 Rock激酶抑制剂的硝基氧衍生物
CA3187693A1 (en) * 2020-07-30 2022-02-03 Zheng Huang Drug conjugates comprising apremilast, and a nitric oxide-releasing moiety and uses thereof
WO2022022669A1 (en) * 2020-07-30 2022-02-03 Biofront Therapeutics (Beijing) Co., Ltd. Dual-functional compounds and methods of use
WO2022090379A1 (en) 2020-11-02 2022-05-05 Nicox S.A. No-pde5 inhibitor for use in treating dry age-related macular degeneration, geographic atrophy and glaucoma-associated neurodegeneration
TW202233623A (zh) * 2020-11-09 2022-09-01 南韓商日東製藥股份有限公司 氮氧化物供與的pde-5及/或pde-6抑制劑化合物及其用途
WO2023005180A1 (en) * 2021-07-30 2023-02-02 Biofront Therapeutics (Beijing) Co., Ltd. Dual-functional compounds and methods of use
CA3239629A1 (en) 2021-12-02 2023-06-08 Nicoletta Almirante Ophthalmic pharmaceutical compositions containing a nitric oxide-releasing phosphodiesterase 5 inhibitor and method for the preparation thereof
EP4233867B1 (en) 2022-02-24 2025-09-03 Nicox SA Pde5 inhibitor for use in the treatment of anterior ischemic optic neuropathy

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020168424A1 (en) 2002-07-31 2002-11-14 Dr. Mohsen Shahinpoor Nitric oxide (NO) donor+cGMP-PDE5 inhibitor as a topical drug for glaucoma
JP2011511022A (ja) 2008-02-07 2011-04-07 ニコックス エス エイ 一酸化窒素供与化合物
WO2016156104A1 (en) 2015-03-31 2016-10-06 Nicox S.A. Nitric oxide donating derivatives of latanoprost free acid
WO2016155906A1 (en) 2015-03-31 2016-10-06 Nicox S.A. Nitric oxide donating derivatives of fluprostenol
WO2017085056A1 (en) 2015-11-16 2017-05-26 Topadur Pharma Ag 2-phenyl-3,4-dihydropyrrolo[2,1 -f] [1,2,4]triazinone derivatives as phosphodiesterase inhibitors and uses thereof
JP2017534658A (ja) 2014-11-19 2017-11-24 ニコックス エス．エー． プロスタグランジンと一酸化窒素供与体との組み合わせ

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60149521A (ja) 1984-01-18 1985-08-07 Eisai Co Ltd 高眼圧・緑内障治療・予防用点眼剤
US4975428A (en) 1988-05-31 1990-12-04 Iolab Corporation Treatment of glaucoma using phosphodiesterase inhibitors
GB9013750D0 (en) 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
IL137429A0 (en) 1999-07-28 2001-07-24 Pfizer Prod Inc Methods and compsitions for treating diseases and conditions of the eye
CN1374953A (zh) * 1999-09-16 2002-10-16 田边制药株式会社 含氮的6－员芳香环化合物
KR100358083B1 (ko) * 2000-02-17 2002-10-25 에스케이케미칼주식회사 피롤로피리미디논 유도체와 이의 제조방법, 그리고 이의용도
DE102005001989A1 (de) * 2005-01-15 2006-07-20 Bayer Healthcare Ag Intravenöse Formulierungen von PDE-Inhibitoren
WO2008075152A1 (en) * 2006-12-15 2008-06-26 Pfizer Products Inc. 1- [4- (sulfonyl) -phenyl] -5- (benzyl) -ih-i, 2, 4-triazol derivatives as inhibitors of carbonic anhydrase for treating glaucoma or ocular hypertension
US7993616B2 (en) 2007-09-19 2011-08-09 C-Quest Technologies LLC Methods and devices for reducing hazardous air pollutants
WO2010096320A2 (en) * 2009-02-18 2010-08-26 Bezwada Biomedical, Llc Controlled release of nitric oxide and drugs from functionalized macromers and oligomers
WO2011032936A1 (en) * 2009-09-15 2011-03-24 Dsm Ip Assets B.V. Nitrooxyesters, their preparation and use
CA2784788A1 (en) * 2009-12-18 2011-06-23 Exodos Life Sciences Limited Partnership Methods and compositions for treating peripheral vascular disease
EP2911656B1 (en) 2012-10-23 2020-12-02 Nicox SA Quinone based nitric oxide donating compounds for ophthalmic use
EP2826491A1 (en) * 2013-07-15 2015-01-21 Nicox Science Ireland Ophthalmic compositions containing a nitric oxide donor
TW201625584A (zh) 2014-07-02 2016-07-16 諾華公司 茚滿及吲哚啉衍生物及其作為可溶性鳥苷酸環化酶活化劑之用途
ES2632808T3 (es) 2014-09-04 2017-09-15 Nicox Science Ireland Compuestos de carnosina donadores de óxido nítrico
EP3088388A1 (en) * 2015-04-30 2016-11-02 NicOx S.A. Nitric oxide donating derivatives of prostaglandins
MX2019013626A (es) 2017-05-22 2020-01-13 Topadur Pharma Ag Modo de accion dual novedoso de activadores de guanilato ciclasa solubles e inhibidores de fosfodiesterasa y usos de los mismos.

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020168424A1 (en) 2002-07-31 2002-11-14 Dr. Mohsen Shahinpoor Nitric oxide (NO) donor+cGMP-PDE5 inhibitor as a topical drug for glaucoma
JP2011511022A (ja) 2008-02-07 2011-04-07 ニコックス エス エイ 一酸化窒素供与化合物
JP2017534658A (ja) 2014-11-19 2017-11-24 ニコックス エス．エー． プロスタグランジンと一酸化窒素供与体との組み合わせ
WO2016156104A1 (en) 2015-03-31 2016-10-06 Nicox S.A. Nitric oxide donating derivatives of latanoprost free acid
WO2016155906A1 (en) 2015-03-31 2016-10-06 Nicox S.A. Nitric oxide donating derivatives of fluprostenol
WO2017085056A1 (en) 2015-11-16 2017-05-26 Topadur Pharma Ag 2-phenyl-3,4-dihydropyrrolo[2,1 -f] [1,2,4]triazinone derivatives as phosphodiesterase inhibitors and uses thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Bioorganic & Medicinal Chemistry Letters，2014年10月28日，Vol.24, No.23，p5460-5465，doi:10.1016/j.bmcl.2014.10.008
Pharmacology & Pharmacy，Vol.5，2014年，p112-116，doi:10.4236/pp.2014.51016
World Journal of Men's Health，2014年04月25日，Vol.32, No.1，p18-27，doi:10.5534/wjmh.2014.32.1.18

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023516891A (ja) * 2020-02-05 2023-04-21 ニコックス エス．エー． 緑内障及び高眼圧症の処置のための組成物
JP7708771B2 (ja) 2020-02-05 2025-07-15 ニコックス エス．エー． 緑内障及び高眼圧症の処置のための組成物

Also Published As

Publication number Publication date
JP2024150732A (ja) 2024-10-23
CA3108551A1 (en) 2020-02-13
AU2019319004A1 (en) 2021-03-25
BR112021001950A2 (pt) 2021-04-27
CN119350347A (zh) 2025-01-24
US20240245684A1 (en) 2024-07-25
KR102836746B1 (ko) 2025-07-21
MX2023012941A (es) 2023-11-13
TWI839375B (zh) 2024-04-21
WO2020030489A1 (en) 2020-02-13
MX2021001503A (es) 2021-04-28
AU2019319004B2 (en) 2025-04-24
CN112566670A (zh) 2021-03-26
US20210322413A1 (en) 2021-10-21
US11980618B2 (en) 2024-05-14
TW202019491A (zh) 2020-06-01
JP2021533152A (ja) 2021-12-02
CN112566670B (zh) 2024-11-12
EP3833395A1 (en) 2021-06-16
KR20210041596A (ko) 2021-04-15

Similar Documents

Publication Publication Date Title
JP7596257B2 (ja) 一酸化窒素放出性ホスホジエステラーゼ５型阻害薬
EP3164395B1 (en) Indane and indoline derivatives and the use thereof as soluble guanylate cyclase activators
EP4100014B1 (en) Compositions for the treatment of glaucoma and ocular hypertension
KR20140003464A (ko) 케모카인 수용체 조절제로서의 인 유도체
CN111606852B (zh) 一种一氧化氮供体型Netarsudil衍生物及其制备方法和用途
JP2018537488A (ja) インダン誘導体、ならびに可溶性グアニル酸シクラーゼ活性化剤としてのその使用
CN111518028B (zh) 一种一氧化氮供体型ripasudil衍生物及其制备方法和用途
ES2292820T3 (es) 2-(3-sulfonilamino-2-oxopyrrolidin-1-yl)propanamidas como inhibidores del factor xa.
RU2785776C2 (ru) Ингибитор фосфодиэстеразы 5 типа, высвобождающий оксид азота
HK40120357A (zh) 一氧化氮释放第5型磷酸二酯酶抑制剂
WO2008075155A2 (en) Carbonic anhydrase inhibitors derivatives
HK40049475A (en) Nitric oxide releasing phosphodiesterase type 5 inhibitor
EP2993172B1 (en) Nitric oxide donating carnosine compounds
HK40049475B (zh) 一氧化氮释放第5型磷酸二酯酶抑制剂
ES2276307T3 (es) Derivados de 1-fenil-2-oxo-3-sulfonilamino-pirrolidina y compuestos relacionados como inhibidores del factor xa para el tratamiento de enfermedades vasculares agudas.
HK40078239A (en) Compositions for the treatment of glaucoma and ocular hypertension
US20110269953A1 (en) Nitrogen and Sulfur-Containing Heterocycle Derivatives
WO2018224419A1 (en) Nitric oxide donating isomannide derivatives
TW202321206A (zh) 轉甲狀腺素蛋白穩定化合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220729

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220729

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230720

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230808

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231025

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231226

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240130

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240402

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240801

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20240808

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241029

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241127

R150 Certificate of patent or registration of utility model

Ref document number: 7596257

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150